Quantum probe enabled Raman spectroscopy for HIV test

量子探针启用拉曼光谱用于艾滋病毒检测

• 批准号: 561111-2020
• 负责人: Tan, Bo
• 金额: $ 2.19万
• 依托单位: Ryerson University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=707355
• 关键词: Quantum; probe; enabled; Raman; spectroscopy

The global HIV prevalence is 0.8% among adults. Early identifying persons with HIV infection allows for timely engagement of treatment, care and prevention services. A fast, selective and accurate test is critical in combating HIV prevalence. At a broader level, there are two approaches for HIV diagnosis. In clinical setting, the most commonly method is through the detecting of immune response to HIV infection. The presence of antibody, antigen or the level of CD4+ cell can be used to confirm the infection of HIV. Most of test kits on market are based on this method and they are quite successful in terms of test accuracy. However, HIV reactivity can be tested only after a certain window time, normally few weeks after the infection. Therefore, this approach is excellent in test long-standing infections, but are sometimes unable to detect recent HIV infections. The advancement of nanotechnology has fueled the development of alternative approach for HIV test. Viral components, such as the HIV virus particle, RNA/DNA or viral proteins are sensed directly by nanosized sensors. The major advantage of this method is that early diagnosis as early as 9-11 days post-exposure can be concluded for adult and for infants younger than 18 months, whose infection cannot be confirmed with immune reactivity. The researchers from Ryerson University and NeuronicWorks have developed a prototype Raman analyzer for the rapid detection of COVID-19 virus particle, virus components and COVID-19 reactivity from saliva and blood serum. The high sensitivity of the device is achieved by quantum-sized semiconductor sensor. Machining learn derived diagnosis algorithms provides computerized interpretation of test results. In this project we will investigate the feasibility of applying the same concept for the detection of HIV particles/particle components as well as immune response. We aim to develop multiplex assay that can be applied to the whole course of HIV diagnosis and treatment. Some of the functions include but not limited to diagnosis HIV at the early stage of infection, interpreting HIV viral load/antibody/antigen for the design of treatment plan and confirm HIV infection for infants.

全球成人艾滋病毒感染率为0.8%。及早查明艾滋病毒感染者，可以及时提供治疗、护理和预防服务。快速、有选择性和准确的检测对于遏制艾滋病毒流行至关重要。在更广泛的层面上，有两种艾滋病毒诊断方法。在临床环境中，最常用的方法是通过检测对HIV感染的免疫反应。抗体、抗原的存在或CD 4+细胞的水平可用于确认HIV感染。市场上的大多数检测试剂盒都是基于这种方法，并且在检测准确性方面非常成功。 然而，HIV反应性只能在一定的窗口时间后进行测试，通常是感染后几周。因此，这种方法在检测长期感染方面非常出色，但有时无法检测出最近的艾滋病毒感染。纳米技术的进步推动了HIV检测替代方法的发展。病毒成分，如HIV病毒颗粒，RNA/DNA或病毒蛋白质直接由纳米传感器检测。这种方法的主要优点是，对于成人和18个月以下的婴儿，可以在接触后9-11天得出早期诊断结论，这些婴儿的感染不能用免疫反应来证实。瑞尔森大学和NeuronicWorks的研究人员开发了一种原型拉曼分析仪，用于快速检测唾液和血清中的COVID-19病毒颗粒、病毒成分和COVID-19反应性。该器件的高灵敏度是由量子尺寸的半导体传感器实现的。机加工学习衍生的诊断算法提供测试结果的计算机化解释。在本项目中，我们将研究将相同的概念应用于检测HIV颗粒/颗粒成分以及免疫反应的可行性。我们的目标是建立可应用于HIV诊断和治疗全过程的多重检测方法。 其中一些功能包括但不限于在感染早期诊断艾滋病毒，解释艾滋病毒载量/抗体/抗原以设计治疗计划，并确认婴儿的艾滋病毒感染。